Repository logo
 
Publication

Secukinumab on Refractory Lupus Nephritis

2021-08Journal article Open access
Simple item page
dc.contributor.authorCosta, Rita
dc.contributor.authorAntunes, Paula
dc.contributor.authorSalvador, Pedro
dc.contributor.authorOliveira, Pedro
dc.contributor.authorMarinho, António
dc.date.accessioned2023-11-16T10:14:21Z
dc.date.available2023-11-16T10:14:21Z
dc.date.issued2021-08
dc.description.abstractLupus nephritis (LN) is the most frequent severe organ manifestation of systemic lupus erythematosus (SLE). About 30% of patients are refractory to treatment. The authors report a case of treatment of LN with interleukin-17-targeted therapy, demonstrating its possible benefit, after reports of T helper 17 cell involvement in SLE pathogenesis. We present the case of a childbearing age woman with SLE, who developed refractory LN despite all the indicated therapeutic options. During follow up, infection with human papillomavirus was detected, a possible trigger, and the following management was based on this discovery. We currently know that cytokines play a major role in tissue damage and interleukin-17 (IL-17) seems to be a fundamental key in SLE and LN, having shown its expression in renal glomeruli and urinary sediment. Thus, it was decided to start treatment with an anti-IL-17A antibody, secukinumab. After starting secukinumab, clinical and biological features improved and complete renal response was achieved.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationCosta R, Antunes P, Salvador P, Oliveira P, Marinho A. Secukinumab on Refractory Lupus Nephritis. Cureus. 2021;13(8):e17198. Published 2021 Aug 15. doi:10.7759/cureus.17198pt_PT
dc.identifier.doi10.7759/cureus.17198pt_PT
dc.identifier.issn2168-8184
dc.identifier.urihttp://hdl.handle.net/10400.16/2891
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherCureus, Inc.pt_PT
dc.relation.publisherversionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439396/pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectcytokinespt_PT
dc.subjectil-17 inhibitor therapypt_PT
dc.subjectimmunosuppressive therapypt_PT
dc.subjectlupus nephritispt_PT
dc.subjectproteinuriapt_PT
dc.subjectsecukinumabpt_PT
dc.subjectsystemic lupus erythematosuspt_PT
dc.subjectth17 cellspt_PT
dc.titleSecukinumab on Refractory Lupus Nephritispt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceUnited States of Americapt_PT
oaire.citation.issue8pt_PT
oaire.citation.startPagee17198pt_PT
oaire.citation.titleCureuspt_PT
oaire.citation.volume13pt_PT
person.familyNameMarinho
person.givenNameAntónio
person.identifier.ciencia-id071D-2A63-84A4
person.identifier.orcid0000-0002-3295-6723
person.identifier.scopus-author-id7004241740
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication4f283ec3-446f-4a55-8451-207d4c4fe994
relation.isAuthorOfPublication.latestForDiscovery4f283ec3-446f-4a55-8451-207d4c4fe994

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Costa-2021-Secukinumab-on-refractory-lupus-nep.pdf
Size:
151.3 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.44 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

UIC - Artigos publicados em revistas indexadas na Medline